An information theoretic phase I--II design for molecularly targeted agents that does not require an assumption of monotonicity
From MaRDI portal
Publication:6642059
DOI10.1111/rssc.12293MaRDI QIDQ6642059
Publication date: 21 November 2024
Published in: Journal of the Royal Statistical Society. Series C. Applied Statistics (Search for Journal in Brave)
trade-off functiondose findingmolecularly targeted agentsphase I--II clinical trialcombination-schedule studies
Related Items (4)
Response-adaptive randomization for multiarm clinical trials using context-dependent information measures ⋮ REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors ⋮ uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials ⋮ Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial
This page was built for publication: An information theoretic phase I--II design for molecularly targeted agents that does not require an assumption of monotonicity
